Key result
Immunomodulatory drugs and proteasome inhibitors for multiple myeloma are associated with cardiovascular sequelae, including thromboembolic complications, cardiac, and vascular toxic effects.
Why the study?
What are the cardiovascular and thrombotic complications associated with novel multiple myeloma therapies?
What are the cardiovascular and thrombotic complications associated with novel multiple myeloma therapies?
Novel multiple myeloma therapies, including IMiDs and PIs, are associated with significant cardiovascular and thrombotic toxicities, highlighting the need for improved screening and preventive strategies.
No takes yet. Share an insight, caveat, or question.
May warrant CV risk assessment during IMiD/PI therapy; leaves open optimal prevention strategies pending prospective trials.
Li et al. (2016) conducted a review in Multiple myeloma. Immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) was evaluated on Cardiovascular and thrombotic complications. Immunomodulatory drugs and proteasome inhibitors for multiple myeloma are associated with cardiovascular sequelae, including thromboembolic complications, cardiac, and vascular toxic effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: